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ABSTRACT: The effectiveness of oral midazolam in pediatric dentistry is controversial. This randomized, controlled,
crossover, double blind clinical trial was conducted in order to study the effect of midazolam, used either alone or in
association with hydroxyzine, during child dental treatment. Thirty seven dental sedation sessions were carried out on
11 ASA I uncooperative children less than five years-old. In each appointment children were randomly assigned to
groups: P - placebo, M - midazolam (1.0 mg/kg), or MH - midazolam (0.75 mg/kg) plus hydroxyzine (2.0 mg/kg). Vital
signs (blood pressure, breathing rate, pulse and oxygen saturation) and behavior parameters (consciousness, crying,
movement, overall behavior) were evaluated every 15 minutes. Friedman and Wilcoxon statistical tests were used to
compare groups and different moments in the same group. Normal values of vital signs were usually registered. Heart
rate increased in groups P and M as the session went on. Group M presented less crying and movement at the first 15
minutes of treatment. Group MH caused more drowsiness at the beginning of the session. Overall behavior was better
in group M than in groups P or MH. Group M produced effective sedation in 77% of the cases, and group MH did so in
30.8%. It was concluded that midazolam was effective and safe, and its association with hydroxyzine did not lead to
additional advantages in pediatric dental sedation.
DESCRIPTORS: Conscious sedation; Hydroxyzine; Pediatric dentistry.
RESUMO: Há controvérsias quanto aos benefícios do midazolam na sedação de crianças durante a atenção odontológi-
ca. Conduziu-se um ensaio clínico controlado, cruzado e duplo-cego para comparar o efeito sedativo em Odontopedia-
tria da administração oral do midazolam, associado ou não à hidroxizina. Trinta e sete sessões foram realizadas em 11
crianças menores de cinco anos, ASA I. Em cada atendimento, os pacientes receberam aleatoriamente o medicamento
conforme os grupos: P - placebo, M - midazolam (1,0 mg/kg); MH - midazolam (0,75 mg/kg) associado à hidroxizina
(2,0 mg/kg). Os sinais vitais (pressão arterial, freqüência respiratória, pulso e saturação de oxigênio) e os parâmetros
comportamentais (consciência, choro, movimento, comportamento geral) foram avaliados a cada 15 minutos. As com-
parações entre grupos e entre momentos de atendimento num mesmo grupo foram estabelecidas estatisticamente
através dos testes Friedman e Wilcoxon. Os grupos P, M e MH não diferiram quanto aos sinais vitais, os quais se man-
tiveram dentro de valores aceitáveis. A freqüência cardíaca aumentou nos grupos P e M com o transcorrer da sessão. O
grupo M esteve associado a menos choro e movimento nos primeiros 15 minutos de tratamento. O grupo MH apresen-
tou mais sonolência no início da sessão. O comportamento geral foi melhor em M do que em P e MH. M produziu seda-
ção efetiva em 77% dos casos, e MH em 30,8%. Concluiu-se que o midazolam foi efetivo e seguro, e que sua associação
à hidroxizina não repercutiu em vantagens adicionais na sedação odontopediátrica.
DESCRITORES: Sedação consciente; Hidroxizina; Odontopediatria.
INTRODUCTION
There are still a fair number of children for
whom the conventional, psychological approach
alone is not enough to provide quality dental care.
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One of the possible sedative drugs in dentistry
is midazolam, a short-acting benzodiazepine
which can provide safe and effective sedation
before surgical procedures18, with anterograde am-
nesia promotion12. When used with other central
nervous systems depressants, midazolam can pro-
duce adverse respiratory events. Its commonly re-
ported effective oral doses range from
0.25-1.0 mg/kg in children (maximum 20 mg). It is
quickly absorbed after administration via the oral
route, can take effect within 15 minutes, reaching
a peak in 30 minutes3, and lasts from 20 to 90 min-
utes7. A number of studies have employed enteral
midazolam for pediatric dental sedation6,14,15,17,24,26,
and even as premedication before nitrous ox-
ide/oxygen analgesia5,20,23, most of them being ret-
rospective studies.
However, the usefulness of midazolam alone is
limited to short-duration procedures, and con-
trolled data are needed to identify safe oral con-
scious regimens which permit longer duration pro-
cedures19.
Wilson25 suggested various sedation protocols
for dental treatment, including the association of
hydroxyzine (1-2 mg/kg) with midazolam
(0.3-0.75 mg/kg). Hydroxyzine is a long-acting (6
to 24 hours) anti-histaminic, H1 antagonist, which
acts as a central nervous system depressant,
showing itself to be a weak anxiolytic drug10,11,16,21.
To date, only a few trials have reported the ef-
fects of midazolam combined with hydroxyzine in
dental practice23. The objective of this paper is to
compare the efficacy and safety of midazolam, ei-
ther alone, or in association with hydroxyzine, in
dental treatments. The hypothesis to be tested is
whether the addition of hydroxyzine would im-
prove the patient’s behavior without affecting vital
signs, thus enabling longer periods of moderate or
conscious sedation.
MATERIAL AND METHODS
The protocol was approved by the Federal Uni-
versity of Goiás (UFG) Ethical Committee; written
informed consent was obtained from the parents of
each child, and all the procedures followed were in
accordance with Resolution 196/96 of Health
State Department, Brazil.
Patients treated at the dental clinic of the
School of Dentistry/UFG from January 2001 until
December 2002 were selected, providing they were
up to 60 months old, ASA (American Society of An-
esthesiologists) I class, were uncooperative after
four sessions of behavior management, and
needed at least three routine restorative visits. Ex-
clusion criteria were tonsil hypertrophy, history of
allergies, drooling or nocturnal snoring.
Children fasted for a minimum of six hours for
solids and two hours for clear liquids. After the
physical examination, the pediatrician adminis-
tered the medication orally, in a random manner,
according to the groups: P (placebo), M (midazolam
1.0 mg/kg) or MH (midazolam 0.75 mg/kg and
hydroxyzine 2.0 mg/kg). The drugs (magistral for-
mulation, Pharmacia Artesanal, Goiânia, Brazil)
were prepared by a pharmacist and were given in a
suspension of 1 ml/kg. In order to prevent sedative
identification, medicine bottles received codes
known only to the pediatrician. Emergency drugs
and equipment were available at all times.
The child and his/her parents rested in a calm
place for 30 minutes, after which the dental treat-
ment began. Local anesthesia was obtained when
indicated, using 2% xylocaine with 1:100,000 epi-
nephrine. When rubber dam use was not possible
due to insufficient dental structure, a mouth prop
was inserted together with cotton rolls and a suc-
tion device. Parents were allowed to stay with their
child during the dental appointment, if they
wanted. Physical restraint was applied in cases
where movement interfered with the completion of
treatment. Following the appointment, written
post-care instructions were reviewed with parents
and the child was discharged when the appropri-
ate discharge criteria were met.
The course of sedation was observed and noted
by an examiner who was blind to the sedative, dur-
ing the medical examination (baseline), and every
15 minutes. The patients’ vital signs which were
evaluated were breathing rate (counting the tho-
rax-abdominal movements per minute); heart rate
and oxygen saturation (as shown on the display of
an Ohmeda 3800 pulse oximeter (Datex - Ohmeda,
Helsink, Finland), whose sensor was placed on the
patient’s big toe); and blood pressure (checked
with an adult-size cuff on the child’s thigh).
Behavior evaluation was based on a scale pro-
posed by Houpt et al.13, which establishes the fol-
lowing scores: sleep - 1 (awake), 2 (drowsy), 3
(asleep); movement - 1 (violent), 2 (continuous), 3
(controllable), 4 (no movement); crying - 1 (hysteri-
cal), 2 (continuous), 3 (intermittent), 4 (no crying);
overall behavior - 1 (aborted), 2 (poor), 3 (regular),
4 (good), 5 (very good) and 6 (excellent). Sedation
was considered successful when overall behavior
scores of 5 or 6 were achieved with no adverse re-
actions in vital signs during the entire procedure.
A score of 4 (good) was not included because it rep-
resents “some difficulty, but all treatment per-
formed”13.
Data were compared using a Friedman
non-parametric statistical test with Winstat soft-
ware (R. Fitch Software, USA), with a significance
index of 0.05. Equivalency was verified between
groups P, M and MH with regards to the parame-
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ters which were observed and, within each group,
the figures obtained at each evaluation (15 min-
utes) and at baseline. When statistically signifi-
cant differences were detected, a Wilcoxon rank
sum test was used in order to select specific differ-
ences among groups.
RESULTS
Thirty seven dental sessions were conducted on
11 patients, three males and eight females. Their
mean age was 40 months (range 20 to 59 months).
One child needed five sessions to complete the
dental treatment plan; four children required four
visits, while two came for two visits. Dental ses-
sions lasted from 27 to 95 minutes; the means for
each treatment were 51.6 (P), 55.2 (M) and 47.3
(MH) minutes (p = 0.839).
Statistically significant differences in the effect
of medications on breathing rate, heart rate, blood
pressure and oxygen saturation showed by P, M
and MH comparisons were not found. The average
values for these parameters are presented in
Graph 1.
Nevertheless, when we considered each group
individually, there were significantly different
changes in the heart rate of groups P and M
(p = 0.000). A crescent heart rate was observed
during the dental treatment, but in M the evalua-
tion at the beginning of the session was similar to
that of baseline. Occasionally all groups had val-
ues as high as 160 to 198 beats per minute.
Oxygen saturation values were above 90% in all
cases, and there were no differences between
groups P, M and MH, or between treatment periods
and baseline values in each group.
When the three groups where compared con-
cerning behavior parameters, whose mean values
are showed in Graph 2, group MH presented more
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GRAPH 1 - Vital signs means observed in placebo (P), midazolam (M) and midazolam associated to hidroxyzyne (MH)
groups, according to baseline (B), at the beginning of dental treatment (T1), after 15 minutes (T2), after 30 minutes (T3)
and after 45 minutes (T4). A - systolic blood pressure, B - diastolic blood pressure, C - breathing rate, D - heart rate.
children asleep (A) at the beginning of the dental
session than did group P (p = 0.018), although this
difference was not true for group M related to
group P (p = 0.059). Crying registered at 15 min-
utes of treatment was better in group M than in
group MH (p = 0.028) and group P (p = 0.025), as
higher scores were related to less crying. Move-
ment at 15 minute intervals had lower scores in
group P than in group M (p = 0.018).
Comparisons of group behavior showed statisti-
cally significant differences only in groups M and
MH, regarding consciousness. In group M, consci-
ousness decreased in the first 30 minutes of treat-
ment (p = 0.014), and in group MH more drowsy
patterns were observed in the first 45 minute peri-
ods (p = 0.018), when compared to baseline data.
Overall behavior analysis showed that group M
was significantly better than group P (p = 0.011)
and group MH (p = 0.022) (Graph 2). Since no seri-
ous adverse events were observed in the groups,
the success rate for each group based solely on
overall behavior scores 5 and 6 was 7.7% (P),
77.0% (M) and 30.8% (MH).
DISCUSSION
The results of this double-blind, randomized,
crossover study indicated that midazolam seda-
tions represent a safe pharmacological technique
for behavior control in pediatric dentistry, al-
though its effectiveness remains questionable.
Some methodological explanations are neces-
sary. While a small number of patients partici-
pated in this study, the crossover design ensured
that patients could be compared to each other.
However, this sample is compatible with Brazilian
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GRAPH 2 - Behavior scores means observed in placebo (P), midazolam (M) and midazolam associated to hidroxyzyne
(MH) groups, according to baseline (B), at the beginning of dental treatment (T1), after 15 minutes (T2), after 30 minu-
tes (T3) and after 45 minutes (T4). A - consciousness, B - crying, C - movement, D - overall behavior, according to
Houpt et al.13 (for additional scores details, go to Material and Methods).
statistics4, where approximately 3.6% of a 3,500
children population needed sedation.
A negative placebo control group was used due
to the fact that, in Brazil, dentists control their
patients’ behavior by non-pharmacological tech-
niques only. Indeed, children’s parents were in-
formed that the use of a placebo would occur.
There is some controversy about the interval re-
quired for the dental procedure after oral adminis-
tration of midazolam, which can vary from 10, 15,
20 or 30 minutes9. In our study we chose 30 min-
utes because of the use of hydroxyzine. If we had
considered midazolam alone this interval could be
reduced, but this would not allow a double-blind
study.
Our results showed that dental appointments
were longer than those related to other midazolam
studies5,19,26. Even in placebo sessions almost one
hour of treatment was observed. This could be ex-
plained by the fact that we rarely abandoned some
treatment, in many cases using physical restraint
in order do finish the procedure.
Our findings in vital signs confirmed the safety
of midazolam. Breathing rate didn’t generally sur-
pass normal values for the age bracket under
study, that is, less than 40 breaths per minute, for
one to five year old children1. In all groups, heart
rate sometimes exceeded the normal 130 beats per
minute (bpm) limit2. However, it is known that the-
se levels can go up to 170 bpm during crying, and
that only persistent tachycardia would require an
investigation2. Indeed, we should recognize that
the high heart rates are compatible with anxiety
states.
By observing behavioral score figures, it can be
noted that consciousness, movement and crying
tended to worsen over the course of dental appo-
intments. In addition, only sleeping was really af-
fected by M and MH. This means that the drugs
weren’t effective in eliminating extremely bad be-
havior, that is, all hysterical crying and violent mo-
vement.
In view of these behavioral parameters, it was
possible to verify that this research was limited, in
that the 15-minute time interval between evaluati-
ons did not allow the investigators to have a more
comprehensive view of the entire session. In fact,
the data could even mask the real situation, and
present either a more favorable or unfavorable re-
sult, depending on the moment the evaluations
were carried out22. On the other hand, in order to
evaluate the behavior of these children during den-
tal treatment under sedation, Fraone et al.8 deci-
ded to film the patients to overcome this bias.
In terms of overall behavior, there were statisti-
cally significant differences in the scores between
groups M versus P, and M versus MH, and they
don’t agree with those in Wilson’s findings25, who
found that the association of hydroxyzine with mi-
dazolam was useful. However, the table proposed13
does not envisage dental treatment carried out un-
der physical restraint, and in our study this met-
hod had to be used in a few instances.
Based on our results, if we consider that
hydroxyzine did not potentiate the effect of
midazolam, the fact that group MH had a lower
dose of midazolam probably led to worse results
than those observed in group M19. Thus, bearing in
mind that polypharmacy must be avoided due to
known adverse reactions, the association hydroxy-
zine-midazolam brings no benefits to dental seda-
tion, although a study affirms that there is no sig-
nificant adverse interaction between midazolam
and hydroxyzine19.
There was an improvement in behavior, howe-
ver, when this benzodiazepine was used. Success
rates for midazolam pedodontic sedation were si-
milar to those found in another study20.
The data in this paper are not meant to encou-
rage dental surgeons to perform routine dental
procedures under sedation, in the dental office.
Much to the contrary, the aim of this paper is to
stimulate more research with a larger patient sam-
ple so that other drugs can be studied in order to
establish the feasibility of pharmacological sedati-
on in pediatric dentistry.
CONCLUSIONS
The differences found in overall behavior scores
between the midazolam (1.0 mg/kg) group and the
others (P and MH) were statistically significant and
clinically relevant. Midazolam showed the best ef-
fectiveness rate (77%). Upon evaluation of the sa-
fety aspect of midazolam and hydroxyzine, both
protocols were found to be safe. Even when signifi-
cant differences were found in some of the physio-
logical parameters, none of the values went beyond
normal limits. According to this methodology, no
advantages were found in the use of the associati-
on of midazolam with hydroxyzine.
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